ImmuCell Co. (NASDAQ:ICCC) Short Interest Up 490.0% in November

ImmuCell Co. (NASDAQ:ICCC) saw a significant growth in short interest in the month of November. As of November 15th, there was short interest totalling 23,600 shares, a growth of 490.0% from the October 31st total of 4,000 shares. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 34,600 shares, the short-interest ratio is presently 0.7 days.

ImmuCell Stock Performance

ICCC stock traded up $0.40 during mid-day trading on Friday, reaching $4.12. 17,047 shares of the stock traded hands, compared to its average volume of 18,967. The company has a quick ratio of 1.44, a current ratio of 3.11 and a debt-to-equity ratio of 0.36. ImmuCell has a 52 week low of $3.34 and a 52 week high of $5.59. The business has a 50-day moving average of $3.62 and a two-hundred day moving average of $3.97. The firm has a market capitalization of $36.71 million, a PE ratio of -8.40 and a beta of 0.56.

About ImmuCell

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.